Selected writing by Loren W. Walker:
- Breaking the Chemical and Engineering Barriers to Lignocellulosic Biofuels: Proceedings of a scientific workshop to develop the roadmap for making lignicellulosic biofuels a practical reality. (2007)
- Trinity Mutipotential Cellular Bone Matrix: A Technical Monograph -- Blackstone Medical, Inc. (2006)
- University of Massachusetts: International Conference on Soils, Sediments and Water -- 20th Anniversary Newsletter (2005)
- "The Medical Device Industry in Southern New England's I-91 Corridor" Report Summary (2004)
- "The Medical Device Industry in Southern New England's I-91 Corridor"
The CT Economy Quarterly Journal (2004)
- "Antimicrobial Alternatives" (2004)
Walker, L., et al. 2001. "Regional differences in hypericin and pseudohypericin concentrations and five morphological traits among Hypericum perforatum L. plants in northwestern United States." Canadian Journal of Botany. 79(10): 1248-1255.
- Walker, L. 1999. Review of the Hypothetical Biogenesis and Regulation of Hypericin synthesis via the Polyketide Pathway in Hypericum perforatum and Experimental Methods Proposed to Evaluate the Hypothesis Portland State University
Medical Device Industry in Southern New England's I-91 Corridor
By: Loren Walker
Editor: Dr. Joseph D. Bronzino (Biomedical Engineering Alliance & Consortium)
Published by Northeast
Utilities System, June 2004
Full 123-page Report available at www.hartfordspringfield.com
News Coverage by The Hartford Courant
Southern New England's I-91 Corridor, as defined for this report, runs through the New Haven and Hartford metropolitan areas of Connecticut and the Springfield metropolitan area of western Massachusetts. At least 15% of New England's total medical device manufacturing employment is consolidated within these three metro areas. The I-91 Corridor also supports a concentration of industries - higher education, health care services and precision manufacturing of metals, plastics and electronics - that are essential resources for the design, development and production of medical devices. Because of the agglomeration of industries already present in the region, Southern New England's I-91 Corridor has great potential to significantly expand its existing medical device manufacturing industry.
This report provides an assessment
of the broad medical device industry in the Interstate-91 Corridor region of
Connecticut and Massachusetts placed in context with the medical device and
technology industry of New England, the greater Northeast and the nation as
a whole. The first section describes the medical device industry in the United
States - its financial and technological trends, major companies, scientific
research base, and geographic distribution. The second section describes the
medical device industry assets and resources of the New Haven, Hartford and
Springfield metropolitan areas - the biomedical research community, higher education
institutes, and precision manufacturing capabilities as well as the trade and
economic development organizations that are in place to support the region's
medical device industry. The third and final section provides a comparison of
the medical device industry in Southern New England's I-91 Corridor with that
of other U.S. metropolitan areas.
The United States is the global leader of the medical device and technology industry. Over the past ten years, the value of the medical device industry stock market index has grown at an average annual rate of 9%. Financial analysts describe the industry as "robust" and "healthy" with "strong top-line growth across the board." The estimated $43 billion medical device industry adds more than $6 billion to the U.S. trade surplus each year. When combined with medical supplies, annual sales for the broad medical device and supply industry are approximately $88 billion. Analysts predict that the "graying of America" coupled with the rapid pace of scientific and technological innovation is positioning the medical device industry for "double-digit growth for years to come." Furthermore, the aging population's demand for ever-better and safer health care products favors medical devices made in the U.S. because the stringent FDA-approval process is internationally recognized as the "gold standard" of product quality and effectiveness.
According to the FDA, a medical device is an instrument, apparatus, implement, machine, implant, reagent or other related article intended for therapeutic or diagnostic use with humans and animals that does not achieve its primary intended purpose through chemical action or metabolization. A medical device, therefore, is anything used for diagnostic or therapeutic purposes other than a drug. Some examples of medical devices are: reusable and disposable instruments used in a clinical setting; surgical instruments; catheters; thermometers, general purpose biomedical lab equipment; diagnostic products, reagents and equipment; coronary stents; orthopedic implants (e.g. artificial hips, knees); electronic implants (e.g. cardiac defibrillators); and electronic/irradiation diagnostic or therapeutic devices such as X-ray machines, MRIs, CT scanners, ultrasound machines and medical lasers.
Medical device manufacturing, as defined for this report, includes the production of: surgical, medical and dental instruments, supplies and appliances including irradiation and electromedical equipment; ophthalmic goods; and optical instruments and lenses. It does not include the production of laboratory furniture, thermometers or in-vitro diagnostic substances. The classification systems employed by the U.S. Census Bureau Current Population Survey and Foreign Trade Department as well as previous reports on the industry provide the basis for this definition of the medical device manufacturing industry.
The design, development and production of modern medical devices requires inputs from a variety of manufacturers, researchers and service providers. The broad medical device manufacturing industry is really an agglomeration of industries that includes: medical device and supply manufacturers and contract manufacturers; higher education/scientific research institutions; health care/biomedical research institutions; mechanical and electrical engineers; precision metal, plastics and electronics manufacturers; and processing, packaging, and testing companies. To make medical devices, companies purchase components and services from other industries. Because of these supply chain linkages, the medical device manufacturing industry produces an economic ripple effect beyond the employment and earnings of medical-device workers.
Medical device industry "hotbeds"
tend to be located in accessible metropolitan areas that have several major
medical centers, research-driven universities and high-precision manufacturing
facilities. Over 28% of the industry's total U.S. workforce of approximately
400,000 is consolidated in the northeastern states where there is an abundance
of world-class research institutions and teaching hospitals. New York, New Jersey,
Massachusetts, Pennsylvania, Connecticut, New Hampshire, Delaware and Rhode
Island each support an above-average concentration of medical device manufacturing
employment, which means that the medical device industry employs a greater part
of the total workforce in each of these states than it does in the nation as
a whole. In the six states of New England, approximately 36,000 residents are
directly employed in the production of medical devices. As many as 28,000 additional
jobs in the region may be indirectly associated with the industry because of
the linkages between medical device manufacturing and other industry sectors.
At least 5,200 of New England's medical device manufacturing industry employees are based in the three metropolitan areas of Southern New England's I-91 Corridor. Perhaps another 4,000 area residents are employed in jobs associated with the production of medical devices. The New Haven, Hartford and Springfield metropolitan areas of Interstate 91 in Connecticut and Massachusetts constitute a major economic corridor in the northeastern United States with a total combined economy that places it ninth in the U.S., just ahead of Dallas, Detroit and Minneapolis-St. Paul.
The approximately 95,000 businesses operating in the Interstate-91 Corridor of Southern New England employ a highly productive workforce of more than one million. The Corridor's 43 universities and colleges, including some of the country's elite higher education institutions, support a student population in excess of 150,000. In addition to nationally-renowned universities, the region is home to several top-ranked medical schools and teaching hospitals that provide the foundation for a thriving biomedical research community. Southern New England's I-91 Corridor, therefore, is an integrated, but polycentric region composed of several urban centers and a host of smaller cities and towns with a critical mass of precision manufacturing, an abundance of higher education institutions, a concentrated health care services industry, and transportation infrastructure that is well-suited to distribution industries.
Regional Industry Profiles:
Within Southern New England's I-91 Corridor there is an above-average concentration of medical device and supply manufacturing business. According to U.S. Food & Drug Administration records of registered medical device manufacturers and the Dun & Bradstreet Marketplace database of medical device manufacturing businesses, there are at least 314 medical device companies currently operating in the region. Furthermore, the Corridor supports more than 18% of New England's FDA-registered medical device manufacturers, and 31% of the FDA-registered contract manufacturers.
From 1996 to 2004, when the size of the total I-91 Corridor workforce decreased by more than 15%, employment in the region's medical device and supply manufacturing industry was also reduced by approximately 2,000 jobs. However, the total number of medical device companies increased over that same period and the concentration of medical device and supply manufacturing employment in the I-91 Corridor is still above-average.
At the beginning of 2004, the "location quotient" (LQ), or relative employment concentration, for the medical device and supply manufacturing industry in Southern New England's I-91 Corridor was 1.9, compared with the national LQ of 1.0. In other words, the proportion of the regional workforce directly engaged in medical device manufacturing was nearly twice that of the United States as a whole. In fact, the concentration of medical device manufacturing employment in Southern New England's I-91 Corridor is higher than it is in 85% of the nation's 333 metropolitan areas. Furthermore, the region's higher education, biomedical research and precision manufacturing resources are well-suited to support increased growth of the medical device manufacturing industry.
The health care services industry is a major regional employer in the I-91 Corridor and some of the region's hospitals are ranked among the very best in the nation. More than 8% of the region's total workforce is employed in the health care services industry. The proportion of hospital and medical center employment in the I-91 Corridor is 60% higher than the national average, exceeding that of Baltimore, Boston or Minneapolis-St. Paul. This extensive health care infrastructure also supports a research community that is active in a wide array of clinical and biomedical engineering research projects.
Southern New England's I-91 Corridor has a long history of precision manufacturing excellence in metals, plastics and electronics. The precision manufacturing and machine tooling industries are key components of the region's industrial sector and important components of the its economic base. The concentration of precision metal manufacturers, plastics processors and electronics manufacturers exceeds the national average for these industries.
The proportion of the regional workforce employed in precision metalworking industries - more than three times the national average - is among the highest in the northeast. Of the 66 metropolitan areas in the northeastern U.S., the I-91 Corridor has the third highest employment concentration in metal forging, machine turning, electroplating and metalworking machinery manufacturing. Additionally, many of the region's manufacturers have had years of experience producing components for the aerospace industry, which requires a level of precision and quality control that is compatible with the rigorous standards the FDA has set for medical device manufacturing. In fact, there are already as many FDA-registered medical device contract manufacturers operating in the I-91 Corridor as there are in the entire state of New Jersey, where medical device and supply manufacturing employment exceeds 20,000.
Higher Education and Research:
The region's workforce is highly educated. Southern New England's I-91 Corridor supports one of the largest concentrations of universities and colleges in the U.S. Many of the I-91 Corridor's higher education institutions have programs and departments representing disciplines that apply to the design, development and production of medical devices including: biomedical engineering; medical and dental schools; materials science; biomedical imaging technology; neuroscience; and precision machining.
Biomedical research at universities, colleges, medical centers and private companies in Southern New England's I-91 Corridor is vibrant and well-funded The region's hospitals, health centers, universities, colleges and private companies collectively received more than $392 million in National Institutes of Health awards in 2002 - more than what was granted to institutions in either Chicago, Ann Arbor or Atlanta.
Collaborative biomedical research projects between area universities and hospitals are ongoing. Research partnerships involving medical device companies are supported by industry liaison and outreach offices within the region's major universities and medical centers. Additionally, several I-91 Corridor-based industry support organizations, such as the Biomedical Engineering Alliance and Consortium (BEACON) and the Bio-Economic Technology Alliance (BETA), play a critical role in facilitating technology transfer from the region's research centers to local industry. Through these and other efforts, the region's medical device companies have enhanced access to a variety of innovative, university-developed technologies.
The I-91 Advantage:
There are significant advantages for medical device manufacturers in Southern New England's I-91 Corridor. Medical device industry executives currently operating businesses in the region confirm that access to area universities and hospitals for R&D support, testing facilities and consultants is an asset. Among other I-91 Corridor location advantages cited by industry executives: access to "top-quality" precision manufacturing personnel and facilities; access to the "vital resources" of skilled labor and raw materials; location ideally suited to serve major northeast markets like New York and Boston; less costly than other locations with an above-average concentration of biomedical device companies; access to transportation networks; and a high quality of life.
The region's medical device companies are growing. Many I-91 Corridor medical device industry executives report that their manufacturing or contract manufacturing companies are experiencing strong fiscal growth; some by as much as 25-30% annually. Several executives commented on plans for expanding their facilities. Included among these businesses are precision manufacturers that have successfully repositioned their business from aerospace component manufacturing to medical device manufacturing.
Finally, the area is accessible and affordable. The New Haven, Hartford and Springfield metropolitan areas are located at the center of the economically and culturally rich Atlantic Triangle formed by New York, Albany and Boston. This part of Interstate 91 is bisected in Massachusetts by the Massachusetts Turnpike (I-90) and in Connecticut by Interstates 84 and 95. With Bradley International Airport at its center, the region offers easy access to major northeast, U.S. and international markets. The cost of living in Southern New England's I-91 Corridor is also significantly lower than it is in many U.S. metropolitan areas including nearby New York and Boston.
This assessment of the New Haven, Hartford and Springfield metropolitan areas reveals that there is a concentrated medical device and supply manufacturing industry along the Connecticut-Massachusetts I-91 Corridor. Moreover, the region possesses sufficient biomedical and scientific research resources and precision manufacturing capabilities to support expansion of the medical device and supply manufacturing industry.
It is notable that the current state
of this industry in the I-91 Corridor has developed without a coordinated effort
to build it. Yet, in the combined resources of the region there is great potential
to grow the existing medical device and supply manufacturing industry, thus
propelling job creation and broad economic development throughout Southern New
England's I-91 Corridor.
return to contents
Originally published in New England Developments, Summer 2004 -- http://www.nu.com/develop/newsletters.asp
New England's Medical
Device Manufacturing Industry: Beyond Boston
By Loren Walker
Long recognized as a bastion of health care services excellence, New England is also a hotbed for the medical device industry. In a recently released study of America's health care economy, the Milken Institute reported that New England has the highest concentration of medical device and supply manufacturing employment of any region in the nation.
New England's world-class universities, state-of-the-art medical centers, and high-precision manufacturing facilities are ideally suited to meet the research, testing and production needs of the modern medical device industry. However, New England's medical device leadership position will not go unchallenged. Other regions are vying for a share of this ascending sector. Through effective interstate collaboration, New England can leverage its vast biomedical research capabilities and industrial resources to ensure retention of medical device manufacturing jobs and foster the industry's growth.
The United States is the global leader of the medical device and medical technology industry, which has been growing at an average annual rate of 9% for the past ten years. Financial analysts describe the industry as "robust" and "healthy" with "strong top-line growth across the board." The estimated $43 billion medical device industry adds more than $6 billion to U.S. trade accounts each year. Additionally, this tech-intensive industry requires an educated workforce, which means that medical device employees earn more on average than their counterparts in other manufacturing sectors.
Analysts predict that the "graying of America" coupled with the rapid pace of scientific and technological innovation is positioning the medical device industry for "double-digit growth for years to come." Furthermore, the aging population's demand for ever-better and safer health care products favors medical devices made in the U.S. because the stringent FDA-approval process is internationally recognized as the "gold standard" of product quality and effectiveness.
Medical device manufacturing businesses are distributed throughout the country. However, 45% the industry's total workforce is based in California and in the northeastern U.S. from Maryland to Maine. The eleven Mid-Atlantic and New England states, which cover an area comparable to California, employ approximately 28% of the nation's medical device and supply manufacturing industry workers. The hub of New England's medical device industry is the eastern Massachusetts' I-495 Beltway of metro areas with Boston at its center.
Although it accounts for less than 6% of Massachusetts' total manufacturing workforce, the medical device industry is an important contributor to the state's economy, according to a report produced for the Massachusetts Medical Device Industry Council (MassMEDIC). The report concluded that the industry has a "ripple effect" on the state's economy beyond the employment and earnings of medical-device workers, primarily because of the important linkages that exist between medical device manufacturers and other industry sectors. To produce medical devices, companies purchase components from Original Equipment Manufacturer suppliers and outsource jobs to a variety of service providers. As a result of these linkages with other sectors, 79 additional jobs are associated with every hundred medical-device jobs and for every dollar of medical device industry output, 22 cents comes from materials and services purchased from other industries in the state. An estimated 36,000 jobs in Massachusetts are related directly or indirectly to medical device manufacturing, according to the MassMEDIC report.
The epicenter of New England's medical device industry is the greater Boston metro area, but that is only half the story. Beyond Boston, other New England metro areas support over 50% of the region's approximately 36,000 medical device manufacturing jobs. If the economic ripple effect from medical device manufacturing observed in Massachusetts is consistent throughout the region then as many as 65,000 New Englanders may be employed directly or indirectly in the production of medical devices.
Medical Device Manufacturing Employment Distribution in New England*
|Eastern Massachusetts I-495 Beltway, Greater Boston||
|I-91 Corridor, New Haven, Hartford, Springfield||
|Rhode Island & Southeastern Massachusetts||
|Eastern New Hampshire & Southerastern Maine||
|Worcester, Massachusetts Metro Area||
*Source: Dun & Bradstreet Marketplace Data, 2004.
The design, development and production of modern medical devices requires inputs from researchers, physicians, engineers and precision manufacturers of metal, plastic and electronic components. In addition to the I-495 Beltway, other parts of New England with a combination of teaching hospitals, research-driven universities and precision manufacturing capabilities, are uniquely positioned to increase their share of the burgeoning medical device industry. Southern New England's I-91 Corridor is one such area.
The I-91 Corridor extending from the Pioneer Valley of western Massachusetts to the Connecticut coastline has great medical device industry growth potential. The New Haven, Hartford and Springfield metro areas support a large research community and nationally-ranked medical centers that provide accessible venues for device testing and evaluation. Additionally, many of the corridor's manufacturers have had years of experience producing components for the aerospace industry, which requires a level of precision and quality control that is compatible with the rigorous standards the FDA has set for medical device manufacturing. In fact, there are already as many FDA-registered medical device contract manufacturers operating in the I-91 Corridor as there are in the entire state of New Jersey, where medical device industry employment exceeds 20,000.
The combined strengths and potential of New England's metro areas suggest a bright future for the region's medical device manufacturing industry. Nationally, the industry is predicted to experience strong and sustained growth over the coming years and decades, creating more good jobs at above-average wages. Because this growth potential has not gone undetected by other states and regions, New England faces stiff competition for medical device industry jobs.
Through interstate collaboration that effectively leverages the region's strengths and resources, New England can maintain its leadership position in medical device manufacturing and medical technology development. In this way, the region will benefit economically and people around the world will benefit from the life-saving devices produced here.
return to contents
Collaboration Grows in Western Massachusetts' Pioneer Valley"
originally published at www.rtacentral.com
By Loren Walker
The Breast Cancer Working Group is a multidisciplinary team of researchers from the Baystate Medical Center and the University of Massachusetts Amherst. Working Group researchers represent a wide variety of scientific disciplines including surgery, pathology, nursing, epidemiology, statistics, molecular genetics, computer science, chemical engineering, and nanotechnology. The Working Group's laboratory-to-clinic approach expedites the translation of scientific discoveries into practical biomedical applications. In addition to university and hospital facilities, Working Group researchers have access to new, state-of-the-art laboratories at the Baystate-UMass Biomedical Research Institute in Springfield. Currently, the Group's collective effort is focused on understanding the nature of pre-cancerous breast lesions that can transition into malignant tumors. Dr. Richard Arenas, Chief of Surgical Oncology at Baystate, and Dr. Joe Jerry, UMass professor of Molecular Medicine, are two Working Group members whose collaboration with colleagues in the UMass Chemistry and Chemical Engineering departments is directed toward translating their medical and biological expertise into practical treatments and preventative therapies for breast cancer.
The COLLABORATIVE APPROACH
Collaboration fuels scientific innovation. In a 2001 report, the National Cancer Institute stated that, "multidisciplinary teams are needed to solve virtually all of the 'big' problems in cancer research." Productive collaboration among mathematicians, biologists, computer scientists, epidemiologists, imaging scientists, physicists, and clinicians is needed to effectively cure and control cancer, the report said. Now, in western Massachusetts, just such a multidisciplinary research team exists. The Pioneer Valley's Breast Cancer Working Group, made up of M.D.s and Ph.D.s from the Baystate Medical Center in Springfield and the University of Massachusetts at Amherst, was formed to investigate the basic pathology of breast cancer and develop more effective interventions to treat and prevent the disease.
Collaboration across scientific disciplines has yielded many important achievements including the discovery of the structure of DNA. In his book on the process of scientific discovery, Francis Crick wrote, "In nature, hybrid species are usually sterile, but in science the reverse is often true. Hybrid subjects are often astonishingly fertile."
The Breast Cancer Working Group is a hybrid coalition of researchers, representing a wide variety of scientific disciplines ranging from pathology and surgical oncology to chemical engineering and nanotechnology, that evolved out of a partnership between researchers at UMass Amherst and the Baystate Medical Center. They meet regularly to help steer the focus of the Group and to allow its direction to influence their own research programs and clinical practice.
At RISK for CANCER
Every year thousands of women are diagnosed with non-cancerous breast disease. Although, so-called benign breast disease is not cancerous, a certain form of the disease, called atypical hyperplasia, is associated with an increased risk of breast cancer. At least 10% of those women diagnosed with atypical breast lesions will develop cancer within one year.
At Baystate Medical Center, physicians frequently detect these atypical hyperplasias and, although they know that some of those patients will soon develop breast cancer, there is nothing to be done about it. Treating all women with atypical hyperplasia would be expensive and very invasive. However, inaction all but assures that 1 out of every 10 women diagnosed will be battling breast cancer within a year. This clinical dilemma, and the problem it poses for physicians and their patients, compelled the Breast Cancer Working Group to direct their focus toward investigating cancer associated with atypical, pre-malignant breast lesions.
Dr. Joe Jerry is a professor of Molecular Medicine at UMass Amherst and the designated leader of the Working Group. His lab uses animal models to study the molecular pathways that mediate susceptibility and resistance to breast cancer and to design targeted therapeutics to prevent it. "Atypical doesn't sound good," Jerry says. "The physician has to tell the patient, 'go home and don't worry about it, but come back and have it checked out often, because you should worry about it.' That's pretty uncomfortable, and at some point people might die from worrying about the disease rather than from the disease itself."
PREVENTION is the BEST TREATMENT
A primary goal of the Working Group is to harness the formidable scientific expertise of its members to achieve a better understanding of the basic cellular and molecular mechanisms that control how atypical hyperplasias transition into tumors. By accurately describing the pathology of tumorigenesis, new drugs can be designed and new methods developed to treat or even prevent breast cancer.
"Stopping the transition would be real prevention. It would be the ultimate prevention," says Dr. Richard Arenas, Chief of Surgical Oncology at Baystate Health Systems and an active researcher in the Breast Cancer Working Group. "If you know that, biologically, there is a link between atypia and the onset of actual breast cancer, presumably because you see it pathologically, then you've identified an actual pathway and there is a possibility of interrupting that pathway," he said.
Arenas has partnered with Jerry to explore how certain anti-cancer drugs affect tumor cells at a molecular level and with other Working Group members in the Chemical Engineering department at UMass Amherst to develop more effective drug-delivery methods. They are interested in the effect that estrogen and prostaglandin-blocking drugs, called aromatase inhibitors and COX-2 inhibitors respectively, have on the activity a tumor-suppressor protein called p53. When working properly, p53 performs an indispensable function in the cellular reproduction process by preventing abnormal cell proliferation. Mutations in the p53 gene and non-mutational changes in p53 function may be associated with up to 45% of all breast cancers.
A GOOD MODEL
In depth experimental analysis of p53's role in breast cancer is currently underway in Joe Jerry's laboratory at UMass Amherst. Jerry has developed a mouse model with a defective p53 gene that consistently develops mammary tumors, which are very similar to those found in human breast tissue. Other animal models for breast cancer have previously been created, but none develop the true ductal hyperplasia that mimics human breast tumors.
"We're seeing a series of different structures in the carcinomas that are very much like humans," he says. This analogous system allows Jerry's research team to experiment with drugs that stimulate the surveillance function of p53 and boost its ability to prevent abnormal cell proliferation.
Through experimenting with the mouse model, Jerry's team has been able to look at how certain drugs stimulate p53's tumor suppression activity. He says they've been able to, "dissect out at least one drug that has good effects on p53 without the negative side-effects on the patient." According to Dr. Jerry, this drug is currently on the market and the observed effect of it on p53 was previously unknown. But he won't release the name of the drug before publishing his findings because, "the results," he says, "have been pretty dramatic."
A BASE for COLLABORATION
Jerry's lab has been working with the Baystate Medical Center for nearly ten years. And, since a state-of-the-art biomedical research facility was opened in Springfield last year, members of the Working Group now also have access to a well-equipped laboratory where they can engage in collaborative research projects.
"It's a resource for both [Baystate and UMass]," says Jerry about the new Biomedical Research Institute in Springfield, "and rather than competing for space at the University or at the Hospital, we have this very flexible resource. So, you can say, 'come on over, use it when you need it. If you've got a good idea, let's go do it.'"
The $90 million Biomedical Research Institute, a joint venture between UMass Amherst and the Baystate Medical Center, is open to Working Group researchers from either campus and to private companies who want to lease space in the facility. Dr. Larry Schwartz, the Institute's Director and UMass professor of Molecular Biology, points out that the collaborative laboratory environment at the Institute has certain advantages over a traditional medical school research facility. "Medical schools," he says, "by and large don't have polymer scientists, computer scientists, chemical engineers and all these other disciplines that a university has."
The Institute is already hosting collaborations between surgery residents and UMass graduate students. This type of partnership affords opportunities for graduate students to work with residents on practical applications for their research and for residents to build their skills in the area of basic science, explains Dr. Arenas. "We not only have graduate students working at [the Institute], but also physicians in training, which may develop into some really interesting synergy and education for both parties," he said.
Bacteriolytic therapy, the use of specially engineered bacteria to target and treat cancerous cells, is the subject of a Working Group partnership underway at the Biomedical Research Institute. Arenas and a surgery resident are collaborating with Dr. Neil Forbes, a UMass professor of Chemical Engineering and member of the Breast Cancer Working Group, to investigate how these bacteria affect certain solid tumors . They hypothesize that the combination of bacteriolytic therapy and standard chemotherapy will more effectively attack and destroy these tumors from both the inside and out.
Nanotechnology in biomedicine is the basis for another cross-disciplinary partnership within the Working Group. Joe Jerry and Dr. Vince Rotello, a UMass Amherst Chemist and Nanoparticle Engineering expert, have secured funding to study how nanoscopic particles can serve both diagnostic and therapeutic roles in the treatment of breast cancer. In one application, the patient is administered a solution of gold or iron nanoparticles that are designed to bind only with the cell receptors and proteins of cancerous cells. "One attached," Jerry explains, "the patient is placed in a magnetic field, which induces a current and causes the particles to heat up, killing the cancerous cells, but without damaging the surrounding tissues."
A STIMULATING ENVIRONMENT
Dr. Jerry is openly enthusiastic about the possibility for developing even more useful therapies and technologies through cross-disciplinary collaborations of this kind. "The UMass researchers," he says, "have the toolbox, they just need somewhere to apply it and the Breast Cancer Working Group has all the resources to identify practical applications for those tools."
Both Arenas and Jerry agree that the environment of the Working Group, where individuals who are all experts in their respective fields are gathered around a central problem, is very intellectually stimulating. "I'm constantly fascinated by what's going on with other people," says Dr. Arenas. Those researchers attracted to the group tend to share this fascination and they're genuinely interested in listening to other people's ideas, he said.
SPREADING the NEWS
Communication is important. Group members try to talk about their work with a wide variety of people at the campuses and within private industry. If an organization or company has a product, idea or technology that they would like to apply toward the breast cancer model developed at UMass or towards developing a clinical trial at Baystate targeting patients with atypical hyperplasias, then the Working Group would like to connect with them, Dr. Arenas said.
Over time, the Working Group will learn more about how to effectively coordinate this sort of multi-institutional, cross-disciplinary collaboration. Eventually, Arenas explains, it could serve as a model for other communities with a hospital interested in branching out into research and a university that wants to apply itself toward something more applicable like medical treatment or medical technology development.
ROOM for GROWTH
When asked why he left a large, prestigious institution in Chicago to come to western Massachusetts Dr. Arenas replies, "Well, I met individuals, actually I met Larry [Schwartz], and Larry told me something very interesting. He told me, 'the biggest disadvantage of coming here is that there's nothing set in stone. There is really no infrastructure in place for this type of collaborative research initiative.' But then he said, 'you know what the biggest advantage of this place is? It's not set in stone. There's no infrastructure here. You can go to your heart's content in terms of where you want to take things.' And he's right."
As more researchers from academia, the medical community and private industry learn about the Breast Cancer Working Group it will continue to grow and the breadth of its collective expertise will widen. This, combined with the enthusiasm and insatiable intellectual curiosity of this hybrid group, ensures that it will also continue to be fertile ground for the ideas and innovations that lead to better breast cancer treatments and better lives for patients.
For a list of Breast Cancer Working Group members go to: http://www.baystatehealth.com/3489/4776/4803/4818/Data_Page/1051630234.html
return to contents
originally published on rtacentral.com
by Loren Walker
Self-sterilizing materials offer manufacturers an alternative way to increase the functionality and value of their products. To explore the science and technology of antimicrobial materials and their applications in manufacturing industries, a representative from AgIon Technologies of Boston and UMass Polymer Science professor Greg Tew came to share their expertise at a recent RTC-sponsored event in Amherst.
The well-known antiseptic properties of silver, "Ag" on the Periodic Table of the Elements, are the basis for AgIon's antimicrobial materials. Dr. Tew and his colleagues at the University of Pennsylvania founded a company called PolyMedix as a result of the biomimetic antimicrobial polymers they invented. Event attendees learned how medical devices, food processing equipment, door handles, school lockers, counter tops, sneakers, toilet seats and a wide variety of other products can be manufactured with self-sterilizing surfaces to prevent the spread of infectious disease.
It wasn't until 1900 that doctors began wearing gauze face masks during surgery. As recently as 1870, some prominent physicians still scoffed at the idea that microscopic organisms could actually make a person sick. In fact, the idea that germs cause disease was only officially embraced by the medical community in 1887 when "germ theory" was described for the first time in an accredited medical textbook. Today, the health risk associated with microbial pathogens is universally recognized and antimicrobial products of all kinds fill supermarket shelves.
Awareness of the risks posed by pathogenic bacteria is most pronounced in hospitals where bacterial infections can have fatal consequences. According to PolyMedix, health care-acquired infections kill 100,000 people annually and result in over $45 billion in related costs. Self-sterilizing surfaces applied to operating tables, medical instrumentation or patient gowns could have significant benefits for patients and the health care industry.
The myriad potential medical applications of antimicrobial biomimetic polymers, called polymetics, gave rise to the PolyMedix company name. The company's founders are researchers at the University of Pennsylvania and the University of Massachusetts Amherst who succeeded in creating synthetic polymers that mimic the antimicrobial activity of the germ fighting, protein-like compounds found associated with many animals and plants. Naturally-occurring antibiotics, like magainins, cecropins and defensins, target and destroy bacteria by degrading the negatively-charged lipid portion of bacterial cell membranes, but do not harm positively-charged mammalian cell membranes. These antimicrobial peptides (small chains of amino acids) dwell on the organism's exterior and serve as the first line of defense against the pathogens in its environment.
PolyMedix's biomimetic polymers have the same antimicrobial activity and mechanism of action as their peptide models, but are much less expensive to make than peptides and they're not susceptible to enzymatic degradation. PolyMedix plans to license their technology to companies that wish to incorporate the synthetic antimicrobial polymers directly into any number of plastic products and textiles or use them as a coating on metal devices and equipment.
The antiseptic properties of silver were recognized by the ancient Egyptians and silver has been used as a wound-healing agent ever since. The bactericidal action of silver is the result of the interaction between positively charged silver ions and the negatively-charged bacterial cell surface. The silver cations attach to the bacterial cell membrane and cause an oxidation reaction that ruptures the membrane and kills the cell.
AgIon Technologies has developed an effective method of harnessing silver's antimicrobial activity. Silver molecules that are bonded to a biologically inert ceramic material called zeolite. Ambient moisture causes antimicrobial silver ions to be released from the ceramic substrate. To the naked eye, the 5 micrometer wide ceramic zeolite "cases" that encapsulate the silver molecules look like a fine powder, which can be easily incorporated into a variety of materials and coatings.
AgIon antimicrobial materials and coatings have already been incorporated into a number of medical, industrial and consumer products including medical packaging, industrial air handling systems, school lockers and running shoes. Through AgIon's antimicrobial technology, traditional manufacturers can add a premium feature that enhances the functionality of existing product lines. The company's engineers specialize in working with manufacturers to determine how best to incorporate AgIon's antimicrobial compound into their existing manufacturing procedures.
But what about the risk of creating resistant bacteria through over-use of antibacterial agents? Instead of attacking the reproductive machinery of bacterial cells, like many anti-biotics and common anti-bacterial agents, both AgIon and PolyMedix antimicrobial products attack the cell membrane. This approach greatly minimizes the risk of creating resistant strains of bacteria, the companies say.
AgIon Technolgies" http://www.agion-tech.com
Dr. Gregory Tew's Research: http://www.pse.umass.edu/tew/tew.html
Antimicrobial Polymers article: http://www.psc.edu/science/2002/klein/new_weapons_for_the_germ_wars.html
return to contents
The Bioscience Industry of Tomorrow Depends on the Students of Today
Published in Mass High Tech: The Journal of New England Technology on 12/1/03
By Loren W. Walker
"The 21st century belongs to the life sciences," declared Massachusetts Senator Edward M. Kennedy in November 2002 at the opening of a new biomedical research facility in Springfield.
It was an appropriate declaration for a senator whose state is positioned at the top of the bioscience industry food chain. What he did not say, however, is that today's students - tomorrow's workforce - are not getting the science education that they will need to take advantage of future opportunities in the life sciences. The bioscience industry revolution is coming, but there may not be a qualified workforce available to meet it upon arrival.
The Massachusetts Biotechnology Council (MBC), the state's biotechnology industry organization, reports that many of its member companies are struggling to recruit workers with the requisite skills to fill technical positions in bioscience companies. This dearth of qualified biotech workers comes at a time when many of the bioscience companies that were founded in the early 1990s are shifting their emphasis from research and discovery to development, manufacturing and commercialization.
During the R&D phase, most, if not all biotechnology companies operate at a net loss, and many succumb under the weight of this financial burden. The Holy Grail for those companies that do survive the initial R&D phase is the successful commercialization of at least one product or service.
"This is where the lion's share of future economic value - and jobs - will be generated," wrote the MBC and the Boston Consulting Group in a 2002 report on the future of the biotechnology industry. "Over the next three years, the great bulk of the biotechnology companies founded in the early nineties will decide where to locate their manufacturing facilities. If Massachusetts does not fight for these jobs it will be an enormous missed opportunity," the report stated.
In Massachusetts and throughout the United States, advances and innovation in the biosciences are accelerating while at the same time student exposure to science in general, and to the life sciences in particular, is decreasing. America's schools, it seems, are in the midst of a science education crisis. In a recent interview with broadcast journalist Charlie Rose, Intel President Andy Grove noted that only about 5% of U.S. students study science or engineering as compared to 30-40% in China.
As the bioscience industry grows, as it is predicted to do throughout this century, it will require an ever-larger, scientifically literate workforce. Without access to a sizeable and qualified worker pool, companies will be compelled to locate their manufacturing facilities elsewhere and it will be our economy that suffers the consequences. Already, they are scrambling to find enough qualified workers to staff manufacturing facilities.
To address what is being called a "chronic shortage" of skilled biomanufacturing workers, a pilot worker-training program was recently initiated in eastern Massachusetts. The "Building Essential Skills through Training" (BEST) program is a collaborative effort of the MBC, state agencies and industry to recruit, screen, hire and train students who are then awarded free tuition and are paid a salary during an intensive four-week training program
Such worker-training programs are necessary to meet immediate workforce needs, but do nothing to address the current science education crisis.
"Young people need to develop life sciences literacy early on," wrote MBC Education Director Cora Beth Abel in the Spring 2003 edition of the organization's newsletter. Ms. Abel also cited research endorsed by the National Science Foundation, which "has shown that the greatest potential impact to student decisions about careers in science begins in the middle school years (grades 5-8)." Therefore, a concerted effort to revitalize science education must begin in the elementary and middle schools.
The revitalization and modernization of science education will require external support from bioscience companies, universities and industry organizations. By supporting early science education, universities will benefit from increased student enrollment in science-intensive programs and bioscience companies will have access to an ample and scientifically literate workforce. Industry-school collaborations would also give students an opportunity to see the human face of the sciences.
Most students have never met a real world scientist. They have no idea what a career in the life sciences looks like, so they don't see it as a viable option. Wyeth BioPharma in Andover, Massachusetts is one company that is trying to remedy this and stimulate student interest in science by organizing presentations at area schools and inviting students to tour working laboratories. If bioscience companies throughout the state adopted similar outreach programs perhaps "scientist" would be more frequently listed along with "fireman" and "astronaut" as a response to the "what do you want to be when you grow up?" question.
However, the classroom is still where students learn fundamental scientific concepts. Modern resources and an updated science curriculum are essential tools that teachers need to build science literacy. Bioscience industry organizations like the MBC and the national Biotechnology Industry Organization (BIO) already have staff and resources dedicated to disseminating modern science-education curriculum, and mobile laboratories like Connecticut's BioBus and Boston's City Lab are bringing state-of-the-art biotechnology labs to students and educators, but their reach is limited.
To truly remedy the current crisis, the MBC asserts that government must commit to making a strong and enduring investment in science education. Some recommendations made by the MBC on how to substantially strengthen science education statewide include: that all elementary schools have a science curriculum coordinator; that motivated science teachers are empowered and supported through access to new curriculum and resources; that professional development and continuing education opportunities are made available to K-12 science teachers; and that a governor's excellence-in-science grant is made available for schools that improve in exposing a broad range of the student population to the opportunities and advantages offered by science education. For a complete list of recommendations for the Massachusetts bioscience industry see the MBC report on-line at www.MassBiotech2010.com
It is estimated that by 2010 up to 150,000 bioscience jobs could be created
in Massachusetts alone. The economic benefit to the state would be substantial.
However, without a scientifically literate workforce, most of those new jobs
will go to other regions or even continents. The only way to ensure tomorrow's
economic growth is by making a significant investment in science education today.
There is no doubt that the 21st century belongs to the life sciences. The question
is: who in the 21st century will reap the rewards?
return to contents
Springfield Hosts Biomedical Implants Conference
Published at rtacentral.com
By Loren W. Walker
It all began in 1905 with steel and a guy named Bill who worked on Cadillacs. Back then, the steel treaters of Detroit were a tight-lipped bunch who guarded their trade secrets closely. Today, the metals and materials industry is an international community, characterized by a spirit of collaboration and networking that fuels innovation and yields important technological advances in everything from automobiles to medical devices.
On Wednesday October 1st, western Massachusetts was host to a conference and networking opportunity for dozens of materials experts from around the region who converged on downtown Springfield to discuss the application of biomaterials in modern medicine. The "Body Parts: Ceramic, Metal and Plastic Biomaterial Implants for Human Body Repair" conference, held at the Sheraton Springfield, was a joint meeting of the American Society of Materials Hartford Chapter, the Western New England Section of the Society of Plastics Engineers and the Springfield-based Regional Technology Corporation (RTC) of Western Massachusetts.
"It's a personal matter," said conference moderator and UConn Institute for Materials Science Director Meyer Ezrin, when a show of hands in the conference room demonstrated that a majority of attendees had some kind of medical or dental implant. Many of the innovative biomaterial implants that have changed the way doctors practice medicine were invented and refined at the Johnson & Johnson's Center for Biomaterials and Advanced Technologies in New Jersey where one of the conference speakers, Dr. Mark Roller, is a principal scientist.
Meyer introduced Dr. Roller, who has overseen the development of biomaterial implants for all parts of the human body, by encouraging him to share his experiences navigating the complicated federal regulatory approval process calling the FDA , "one of the toughest bodies to get anything through."
Roller focused his talk on bioabsorbable materials that degrade over a known period of time after implantation and on medical devices in FDA Class III, which is the most strictly regulated group of devices - those that support human life. He described several devices created through advanced polymer chemistry that are more effective and less invasive than traditional implants like metal screws.
A bioabsorbable crosspin designed to hold together the bone, tendon and hamstring after a severe anterior cruciate ligament (ACL) injury gives the ACL plenty of time to heal before it degrades four years after implantation. And, instead of screws, "smart" polymeric cranial fixation devices can be molded to fit any shape of skull and, as an aid to the physician, change color when heated indicating a temporary state of malleability.
Meyer introduced the second conference speaker, UConn Department of Metallurgy and Materials Engineering assistant professor Dr. Mei Wei, whose research is directed toward the development of "bioactive" materials that behave just like the bone and tissue of the human body that they are designed to replace, making artificial implants more like organic transplants.
Dr. Wei focused her talk on the properties of bone replacement materials made from a composite of synthetic polymers and hydroxyapatite (HA), a naturally occurring and fundamental part of bone composed primarily of calcium and phosphate.
Cell cultures of HA prepared in Dr. Wei's lab are chemically identical to HA found in bone, but Wei cannot yet "grow" a bone from a petri dish. The still poor mechanical properties of cell-cultured HA require that it be mixed with synthetic polymers to make implants that actually mimic the mechanical properties of natural bone and are suitable for use in bone replacement surgery.
Springfield was an ideal site for the October 1st "Body Parts" conference because of the region's history in precision manufacturing and proximity to several universities with active materials research and biomedical engineering programs, including: the internationally renowned Polymer Science and Engineering Department of UMass Amherst, the Biomedical Engineering Department of Western New England College, the UConn Institute for Materials Science and the multi-institutional, biomedical engineering program of the Biomedical Engineering Alliance and Consortium (BEACON) based in Hartford.
The international metals and materials community in western Massachusetts and the Connecticut-Massachusetts "Knowledge Corridor" is represented by the Materials and Manufacturing Technology Network (MMTN) of the RTC.
return to contents
"The New Golden Age of Vaccines is Green"
by Loren Walker
previously published on OneScience.com 5-26-03
ABSTRACT - Plants are the most efficient protein producers on the planet.
Through genetic transformation of their nuclear or chloroplast genome, plants
like the tomato and the potato can be induced to synthesize a variety of immunogenic
proteins that function as vaccines when ingested by animals or even humans.
The technology promises inexpensive and easily administrable vaccines. In spite
of ongoing technical challenges and concerns about the safety of producing vaccines
and other pharmaceuticals in green plants, plant-based vaccines may prove to
be the most useful and widely accepted innovation to come out of agricultural
biotechnology to date.
"If it doesn't kill you it'll make you stronger." In 1796, British physician Edward Jenner took that aphorism to heart when he conceived of a revolutionary way to prevent one of the most deadly diseases of his time, the "speckled monster," smallpox. Jenner discovered that patients who consumed small quantities of ground-up cowpox lesions became immune to smallpox, which was known to be a related disease. Jenner's invention of the first vaccine was heralded as one of the most important public health innovations of all time and the science of immunology was born.
Fast forward to the year 2003. Vaccination has been the most widely used public health tool of the twentieth century. Hundreds of thousands of deaths from smallpox, measles, diphtheria, polio, pertussis (whooping cough), tetanus and other diseases have been prevented by childhood immunization. Revolutionary advances in molecular biology have spurred the development of new, highly specific vaccines against modern plagues like hepatitis, HIV and cancer. However, as immunological drugs become more advanced, they are also becoming more complicated, more labor intensive to produce, and more expensive. Even relatively simple injectable vaccines can cost between $40 and $100 per dose.
The high cost and difficulty of transporting and administering injectable vaccines to remote populations in the developing world means that many children go without necessary vaccines and consequently many will die from preventable illnesses. The problem is not theirs alone to bear. Uncontrolled outbreaks have global consequences. In a world where anyplace is just a plane flight away, the threat of an epidemic anywhere poses a risk to everybody everywhere. "Mysterious Chinese respiratory virus kills nine Canadians," read the headlines this week.
We now know that an uncontrolled virus anywhere is a threat to health everywhere.
Clearly, vaccines that are inexpensive and easily administrable could save hundreds of thousands of lives in developing countries and prevent the spread of disease to other parts of the world. In the early 1990s a pioneering molecular biologist, Charles Arntzen, took the first step toward creating just such a vaccine. He conceived of a way to inexpensively synthesize immunogenic antigens by exploiting the protein-assembling machinery of plant cells. [1, 2]
Classic vaccines, like the one invented by Jenner in the 18th century, are essentially very small doses of potentially harmful pathogens. Inherent in their application is the remote but real risk that the microorganisms that compose that vaccine will actually cause the disease they are supposed to prevent. That is why vaccine subunit preparations are the preferred method of immunization today. The subunits cannot cause an infection on their own because they are simply antigenic proteins and do not contain any of the pathogen's genes. Plant-based vaccines are like subunit preparations. The plants are genetically transformed to express antigenic proteins, but they do not have the genes that would enable the pathogen to form. Arntzen realized that plant-based vaccines would be as safe as subunit preparations, that they would cost a lot less and would not require refrigeration.
In 1999, after spending several years researching plant-based vaccines, Arntzen testified to the Senate Committee on Agriculture, Nutrition and Forestry on what he called the "dramatic potential of plant genetic engineering to directly benefit human health." He described how plant-based vaccines could prevent the nearly 2.5 million annual child deaths that result from enteric diseases caused by cholera or virulent strains of E. coli. As evidence of broad-based support for the technology, Arntzen referred to a World Health Organization conference on Child Vaccination where edible vaccines were highlighted as a recent technological advancement that could profoundly impact public health. 
One reason that these biotech vaccines are believed to hold such enormous potential for developing countries is not high-tech at all. It is simple logistics. In contrast to injectable vaccines, plant-based vaccines would not only be cheaper, but they would be easier to administer and could potentially be grown near the population targeted for vaccination, according to Carol Tacket, MD at the University of Maryland. 
The significant public health implications of Arntzen's concept became apparent to investigators within the immunology and agricultural biotechnology research communities. Since he first conceived of the idea in the early 1990s, an ever-growing number of researchers at academic and commercial laboratories have taken up the call to develop vaccine-synthesizing transgenic plants. These scientists and their respective institutions have shown conclusively that when genetically transformed, plants like the tomato and the potato can be induced to synthesize a variety of immunogenic proteins that function as vaccines when orally ingested by animals or even humans.
As recently as October, 2002 the Boyce Thompson Institute for Plant Research reported that plant-based vaccines could provide "an economical alternative to fermentation systems." They point to animal and human studies that suggest "that ingestion of transgenic plants containing vaccine proteins causes production of antigen-specific antibodies in serum and mucosal secretions." 
Arntzen, former director of the Boyce Thompson Institute, is now based in Arizona at the Arizona Biodesign Institute in Tempe. He and his colleagues are working on early-stage clinical trials of potato-based vaccines for hepatitis B, virulent strains of E. coli and the Norwalk virus. They too have convincing evidence that ingesting vaccine-laden plant tissue triggers the production of antibodies in animals and humans. As investigators report success during early clinical trials Arntzen emphasizes the incredible production potential of plant-based vaccines. He estimates that one could vaccinate all of China against hepatitis B using plants growing on only 125 acres. 
Researchers at the University of Rochester have set their sights on today's most infamous plague: cancer. More than 80% of cervical cancer cases in women are linked to the sexually transmitted Human Papillomavirus (HPV). U. Rochester scientists are working with Arntzen and his colleagues at the University of Arizona to develop a plant-based vaccine against HPV. 
An anti-HIV vaccine is the holy grail of AIDS prevention and treatment research. The widespread incidence of AIDS in developing countries, especially Africa, necessitates that any treatment for the disease be inexpensive, stable enough for delivery to remote communities and easily administrable. Plant-based vaccines meet these requirements and, because they are orally administered, may elicit the strong mucosal immune response required to stop the transmission of the virus during sexual contact. At Jefferson University in Philadelphia, immunology pioneer Hilary Koprowski and his colleagues have transformed spinach plants to express a protein that is key to HIV replication. This is a first step toward the creation of a comprehensive plant-based vaccine for HIV1. [8,9]
Other research institutions and private companies that have followed Arntzen's lead include: Loma Linda University where researchers are developing insulin producing potatoes for the treatment of juvenile diabetes; the French company Meristem Therapeutics, which is developing transgenic corn designed to combat cystic fibrosis; and several companies that are looking past vaccines toward the pathogen-fighting antibodies they induce. Dow, Monsanto and Epicyte Pharmaceuticals have research programs dedicated toward the development of monoclonal antibodies that can be used as therapeutic agents for the diagnosis and treatment of a variety of diseases.  And, in India, scientists took a first step toward an edible, plant-based vaccine against anthrax when they successfully integrated the protective antigen gene into the nuclear genome of tobacco. 
Decades of painstaking research in molecular biology have provided the requisite tools for the technology of plant-based vaccines. Some of the most important tools include amplification of DNA via the ubiquitous polymerase chain reaction (PCR), Agrobacterium-mediated genetic transformation of plant cells, and an ever-increasing understanding of the all-important "promotor" sequences that augment expression of the desired proteins.
So, whether they are developing vaccines or the related antibodies, all the research institutions and companies involved in this technology are working with the same biological paradigm: DNA sequences are the blueprints for protein production. Plants are exceedingly efficient protein producers. Therefore, if it's proteins that you want - vaccines, antibodies, or even bioplastics - then the most efficient way to produce them is within plant cells.
Scientists investigating plant-based vaccines at the Biotechnology Foundation Laboratories see themselves as "poised on the brink of an enormous medical breakthrough - one that could alter the face of the world of healthcare in the next century."  In addition to the financial and logistical benefits of employing plant-based vaccines, proponents of the technology point to the advantage of increased patient safety. Unlike animal-based bioreactor systems, plants are incapable of harboring potentially harmful animal or human pathogens. Additionally, plant-based vaccines are edible and therefore do not require syringes, which pose the threat of infection to recipients.
These characteristics have convinced many researchers and science reporters that plant-based, edible vaccines are the key to effective, more widespread vaccination. And, as observed by at least one other reporter, "Until everyone has routine access to vaccines, no one will be entirely safe."  Public interest in the technology was verified last year when, in a survey commissioned by the biotechnology industry, plant-based vaccines were named as one of the five most important biotechnology innovations of 2002. [14, 15]
In an era when anything genetically modified is a potential target for biotechnology opponents, it seemed as though the life-saving potential of plant-based vaccines might make them immune to criticism.
Then there was the Prodigene incident.
The Prodigene Company is a leader in the development of plant-based vaccines and holds several major patents relating to the process of using plants as bioreactors to make vaccines. [2,4] Prodigene genetically engineered corn plants to produce a vaccine to protect baby pigs from a gastrointestinal disease. A Nebraska farmer was contracted by the company to grow an experimental plot of the biopharmaceutical corn in his field. The farmer followed the containment guidelines for growing biotech crops as outlined by the United States Department of Agriculture.
The bioengineered corn crop was harvested in the fall of 2001. The following spring the owner of the test field decided to plant soybeans there. In accordance with USDA guidelines Prodigene sent inspectors to the field in the summer of 2002 to ensure that none of the genetically engineered corn was sprouting amid the newly planted soybeans. They did not find any stray corn so inspections were discontinued in August of that year.
However, when USDA inspectors arrived at the field in November of 2002, after the soybean harvest, they observed stubble from corn stalks in the ground suggesting that at least some of the bioengineered corn had been harvested along with the soybeans. The USDA then tracked the soy harvest to a storage elevator where the soybeans had been mixed with the harvest from several other farms. The USDA incinerated of all 500,000 bushels, and ordered Prodigene to reimburse the farmers $3 million for their destroyed harvest and forced the company to pay an unprecedented $250,000 fine. 
The Prodigene incident underscores concerns about the potential risks of the technology. Opponents of biopharming and plant-based vaccines claim that the potential of the technology is overshadowed by the increased risks it poses. Like all genetically modified crops there is the concern that transgenes from vaccine-producing plants will inadvertently be incorporated into wild plants by unintended cross-pollination. However, the fact that these particular transgenes code for biologically active, pharmaceutical proteins poses an even greater threat to the environment and to humans, according to Joe Cummins of the Institute for Science in Society. 
Cummins describes a scenario where vaccine pollutants spread airborne as pulverized plant debris or leech out of plant roots into the soil and groundwater. Humans or animals living in the area may inadvertently ingest the vaccine by drinking vaccine-polluted water or by breathing vaccine-contaminated dust. Exposure to the immunogenic antigen in this way can stimulate oral tolerance to the vaccine, which would render it useless as an immunizing agent. Individuals tolerant to the vaccine would not produce antibodies in response to intentional vaccination and therefore would be defenseless against the pathogen.
Even staunch supporters of agricultural biotechnology see plant-based vaccines
and plant-based pharmaceuticals in general as more risky than earlier generations
of genetically modified crops. "We're one of the strongest defenders of
using biotechnology in agriculture. But this is something different," said
Rhona Applebaum, executive vice president of the National Food Processors Association.
In response to the Prodigene incident, the USDA is proposing stronger regulations for bioengineered food crops including: setting aside fields and equipment exclusively for experimental crops, marking biopharm plants as distinct, perhaps by dyeing their leaves a different color, and moving experimental fields out of the Midwest's Corn Belt. 
So, while transgenic crop vaccines may indeed hold enormous potential as a source of human and animal therapeutics, Joe Cummins and his colleagues at the Institute for Science in Society remind us that the risks to human health and to the environment are real, and in his view, the only way to safely produce these crops is to use controlled production facilities like greenhouses.
Even as plant-based vaccine critics like Cummins are trying to generate public awareness about the risks of the technology, scientists in the laboratory are still trying to overcome several technical obstacles to the practical application of producing immunogenic antigens in plants.
The primary challenges revolve around controlling the expression levels and stability of antigen proteins in plant cells. In order for plants to be efficient delivery vehicles for vaccines, the immunogenic protein has to be expressed at high levels in the plant cells. Low transgene expression levels have plagued a number plant-based vaccine experiments.  Insertion of the immunogenic protein-encoding gene into the chloroplast genome instead of into the nuclear genome may help increase expression levels. Several investigators have demonstrated increased transgenic protein expression in the chloroplast genome.  An additional advantage of chloroplast transformation is that the chloroplast genome is not inherited by the next generation of plants, so the transgene(s) cannot be passed on, thereby eliminating the risk of unintentional cross-pollination. Finally, the stability and immunogenicity of plant-produced antigens has been found to vary significantly. This is believed to be a problem inherent to oral delivery, which will have to be overcome. 
Overcoming these technical difficulties will take time and money, a lot of money. Charles Arntzen and his colleagues have already spent $5 million on their work to develop effective plant-based vaccines, but they will need at least $20 million to get through the full battery of clinical trials required for FDA drug approval. [6,7] A possible source of funding may be the Bill and Melinda Gates Foundation, which is already actively working to expand immunization programs in poorer nations. A grant and the accompanying endorsement of the Gates Foundation would not only provide much needed funds for Arntzen's research, but might also establish the technology of plant-based vaccines and pharmaceuticals as the most promising innovation to come out of agricultural biotechnology to date.
1) Blake, M.E. and Arntzen C.J. "Edible Vaccines." http://www.nal.usda.gov/pgdic/Probe/v5n1/lead.html
2) Arntzen, C.J., et al. 2000. "Vaccines Expressed in Plants" United States Patent # 6,136,320
3) Statement of Charles J. Arntzen, Ph.D. President and CEO Boyce Thompson Institute for Plant Research, Inc. Ithaca, New York Senate Committee on Agriculture, Nutrition and Forestry. 10/6/99
4) "Broad Patent Received for Plant-based Edible Formulations." Virus Weekly, 11/07/2000, p6, 2p
5) "Prospects for edible vaccines limited, but still promising." Virus Weekly, 10/2/2002, p20.
6) Wherry, R. 1/20/2003. "Planting Hope." Forbes. 171(2): 110
7) Council for Biotechnology Information. "Edible Vaccine Holds Promise for Prevention." http://www.whybiotech.com/index.asp?redirect=HPV%2Ehtml
8) Henderson, CW. 6/4/2001. "Tat Protein, Component Of HIV Vaccines, Has Been Successfully Produced In Spinach." AIDS Weekly. P18.
9) Young, Emma. 4/20/2002. "How long before HIV vaccine is growing in
a field near you?" New Scientist. 174(2339):13.
10) Aziz M.A., Singh S., Anand Kumar P., and Bhatnagar R. 12/2002. "Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax." Biochemical and Biophysical Research Communications. 299(3): 345-351.
11) Biotechnology Foundation Laboratories -- http://www.jci.tju.edu/bfl/index2.htm
12) Hepstead, Hemel. Jul-Sep. 2001. "Edible vaccines the key to better immunization." Appropriate Technology.
13) Langridge, W.H.R and Rusting, R. 9/2000. "Edible vaccines." Scientific American
14) Council for Biotechnology Information. "Cancer Fighting Tomato Tops America's 2002 Best in Biotech" http://www.whybiotech.com/index.asp?id=2243
15) Lemonick, M. 10/18/2002 "Best Inventions - Tomato Vaccine" Time. http://www.asu.edu/asunews/inthenews/Time-arntzen_120602.html
16) "Alarm Bells Going Off About Grains that Contain Vaccines." 12/26/2002. Los Angeles Times. http://www.wcfcourier.com/topnews/021226alarm.html
17) Cummins, J. "Risks of Edible Transgenic Vaccines." http://www.i-sis.org.uk/full/PharmageddonFull.php
18) Daniell H.; Khan M.S.; Allison L. 2002. "Milestones in chloroplast
genetic engineering: an environmentally friendly era in biotechnology."
Trends in Plant Science. 7(2):84-91.
return to contents
"The 'Third Wave' of Agricultural Biotechnology"
by Loren Walker
previously published on OneScience.com 3-6-03
On March 16th to the 19th hundreds of scientists will gather in Québec, Canada at the Hotel Loews Le Concorde for a major, international conference on plant-made pharmaceuticals. The 2003 Conference on Plant-Made Pharmaceuticals is sponsored by organizations on the leading edge of this technology, which is otherwise known as "molecular farming" or, simply "pharming." According to the conference organizers, the event will provide a "unique meeting opportunity between biopharma and plant-based protein production." The over 700 participants that are expected to attend the meeting will make this gathering of molecular farming specialists the largest ever held.
The Québec meeting is the 2003 edition of two previous conferences. Two hundred fifty participants from academia and emerging companies discussed scientific issues at the first conference, held in 1997 in Saskatoon, Canada, where the term "molecular farming" debuted. The second conference, held in London in 1999 saw 450 participants including a "modest contingent of representatives" from the pharma-biotech and financing community.
This year's conference, organized primarily by the International Molecular Farming Association, seeks to continue exploring the scientific foundations of molecular farming as well as the current prospects for funding and the future financial development of the fledgling industry.
According to an official conference press release, "the three-day program begins with 90-minute plenary sessions where world-class keynote speakers relate present challenges and future benefits of plant-made pharmaceuticals. The rest of the day is made of dual-track symposia on technology, business and stewardship, and presentations of platforms, products, applications and technologies, brought to you by top scientists and experienced businesspersons. All frequently asked questions of plant-based production of biologic drugs will be addressed: production cost, capital savings, capacity, introduction to clinical trials, protein quality (glycosylation), containment, biosafety, product regulations, and many others." English will be the official language of the conference and no simultaneous translation will be provided.
Attending the conference will be senior managers of biopharmaceutical and pharmaceutical companies (business development, protein production, product development, quality assurance), top scientists from academia and corporations, senior representatives from novel protein production companies, representatives from governments, regulatory agencies, industry and consumer groups, and members of the press.
Companies presenting at the 2003 Conference on Plant-Made Pharmaceuticals include: Biolex, Ceres, Dow AgroSciences, Epicyte Pharmaceuticals, Greenovation Biotech, Medicago, Meristem Therapeutics, Monsanto Protein Technologies, Plantigen, Planton, Prodigene, SemBioSys, Icon Genetics, and Syngenta.
A new and rapidly expanding branch of agricultural biotechnology, plant molecular farming is considered the "third wave" of industry advancement. The first wave yielded products engineered to be resistant to insect pests (like Bt-corn and Bt-cotton) or herbicides (like Roundup Ready soybeans). The second wave involved producing plants with value-added characteristics like salt-tolerant tomatoes and high-lysine corn. The third wave of agricultural biotechnology is plant molecular farming, which is defined by the Canadian Food Inspection Service as, "the cultivation of plants for industrially, medically, or scientifically useful biomolecules, rather than for traditional uses of food, feed, or fibre."
The bioproducts of molecular farming (pharmaceuticals, fibers, fuels, adhesives, etc.) are synthesized using the existing protein-assembling machinery in plant cells. Plants are the most efficient protein-producers on the planet. Well-studied plant systems like alfalfa, corn, moss, potatoes, tobacco, safflower and others can be genetically transformed to yield a variety of non-native proteins on a large scale, at a lower cost than is possible with current manufacturing methods and with freedom from potential viral and animal protein contamination. However, to date there are no FDA-approved drugs containing material from pharma plants.
Manufacturing these protein-based drugs via the current procedure of using mammalian cells is very expensive, is prone to viral and animal protein contamination and is not well suited to very large-scale production. Industry lobbyists and spokespersons for companies with molecular farming programs point to the high cost and limited availability of these drugs as evidence for why plants should be used to produce pharmaceuticals. Monoclonal antibodies (MAbs), for example, are expensive pharmaceuticals that are also in high demand. MAbs can be produced in transgenic plants for a fraction of the cost and on a much larger scale than would be possible with mammalian cells.
The molecular farming research company Agrecetus makes human antibodies in corn plants. They have created a strain that they claim yields 1.5 kilograms of pharmaceutical-quality antibodies per acre of corn. Vikram M. Paradakar, an Agrecetus scientist interviewed by the journal Trends in Plant Science (2001 Vol. 6 No. 5), predicts that his company "could grow enough antibodies to supply the entire U.S. market for our cancer drug - tens of thousands of patients - on just 30 acres."
In spite of the optimistic language, several sessions of the 2003 Conference on Plant-Made Pharmaceuticals will address the ongoing technical difficulties inherent to producing human drugs in plant systems. Dr. Jon McIntyre, of Monsanto Protein Technologies, is one of several researchers that will discuss their investigations into the potential problems of using plant-produced MAbs on human patients. Carbohydrate moieties found on plant-produced MAbs are not native to humans and may elicit an antagonistic immune system response.
The ability to make plants into protein factories for drug production is undeniably a technology that could radically transform the way medicines are made. However, this enormous potential is not without its risks.
Last year's widely publicized "Prodigene Incident," when maize modified to produce a pharmaceutical protein was found growing in fields of normal soybeans in Iowa and Nebraska, has focused public scrutiny on plant-made pharmaceuticals.
The public, the food industry and government regulators are now adamant that this new generation of GM products be rigorously contained, even going so far as top insist that only non-food crops be used. Therefore, concerns about the untoward effects of molecular farming and strategies for minimizing risk will feature prominently during the conference.
Conference keynote speaker and Washington Post reporter Justin Gillis writes, "Plant-made pharmaceuticals (PMP's) promise better, cheaper drugs produced from a green, natural and renewable source which resonates well with the general public. However, as all new technologies, PMP's raise their lot of concerns."
As if to address these concerns, major portions of the Plant-Made Pharmaceuticals 2003 Conference program are dedicated to policy sessions such as the Science Symposia on "The Science of Biosafety and Biovigilance" and the Stewardship and Regulatory Symposia on "Stringent Containment and Biomass Production Regulations."
The perceived threat that transgenes will contaminate nearby wild and/or domesticated plants is a major public relations challenge for the molecular farming industry. Several researchers attending the conference will discuss scientific solutions to the problem of how to contain and control the expression of transgenes.
Dr. Pal Maliga of Rutgers University will present a study of chloroplast expression of recombinant proteins. The chloroplast genome is not passed from parent plants to their progeny and is therefore believed to safer domain for the production of novel proteins than the nuclear genome. Dr. Liz Foster of Agriculture and Agri-Food Canada will present her company's research on how pollen coat targeting technology can be used to prevent pollen-mediated outcrossing.
Issues of physical containment will be addressed by a variety of speakers who will discuss the pros and cons of growing pharm plants in enclosed, underground and geographically isolated sites.
Even the conference entertainment reflects an increased emphasis on safety. On Tuesday night conference goers will be treated to a musical performance by the band "The Biosafeties" - formerly known as "The Biohazards."
For further information: see conference website www.cpmp2003.org or contact:
Mr. François Arcand, President, cPMP, Québec City, email@example.com;
Ms. Elizabeth McKay, SPEQM, Québec City, firstname.lastname@example.org;
Ms. Cate McCready, BioteCanada, Ottawa, CMcCready@biotech.ca
Related On-line Resources:
2003 Conference on Plant-Made Pharmaceuticals
Plantigens and Plantibodies from Transgenic Plants
Pew: Biopharming Could Reap Benefits But Must Be Carefully Regulated
Pharm farming: It's Not Your Father's Agriculture
Molecular Crop Safety: Biosafety in Plant Biopharming
Biohazards: The Next Generation? Genetically Engineering Crop Plants that Manufacture Industrial and Pharmaceutical Proteins
return to contents